Photocure fundamentale forhold (PHO)

TekBot · mars 25, 2021, 10:27am

Photocure ASA - Initiation of a share buyback

Oslo, Norway, 25 March 2021: Photocure ASA (“Photocure” or the “Company”) has
decided to initiate a buyback of up to 72,500 of its own shares for a total
maximum amount of NOK 10,875,000. The buyback program may be carried out in the
…

Vis børsmeldingen

period from this announcement and until 22 April 2021.

The purpose of the program is to acquire shares that can be used as settlement
in the Company’s share-based incentive scheme. Any acquired shares may also be
used for subsequent reduction of the capital of the Company or to meet
obligations arising from debt financial instruments that are exchangeable into
equity instruments in compliance with the EU Market Abuse Regulation article 5,
and as approved by the general meeting of the Company.

The buybacks will be made in accordance with the authorisation granted to the
board of directors by the Company’s annual general meeting held on 10 June 2020.
According to the authorisation, up to 2,397,603 may be purchased at a minimum of
NOK 0.50 and a maximum of NOK 150 per share. The authorisation is valid until
the annual general meeting on 20 May 2021.

All acquisitions under the buyback program will be executed on Euronext Oslo
Børs. The execution of any repurchases will depend on market conditions, the
buyback programme may be discontinued at any time and the Company may resolve to
terminate the buyback programme before the threshold set out above is reached.

Photocure owns 15,666 own shares in the Company as of the date of this
announcement.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This is information is made public by the Company pursuant to the EU Market
Abuse Regulation article 5, as supplemented by Commission Delegated Regulation
(EU) 2016/1052, and is subject to the disclosure requirements pursuant to
Section 5-12 the Norwegian Securities Trading Act.

Kilde

TekBot · mars 25, 2021, 10:37am

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 25 March 2021: Participants in Photocure ASA’s (“Photocure” or the
“Company”) share option program have on 25 March 2021 exercised a total of
102,533 options distributed as follows:
…

Vis børsmeldingen

· 6,533 options exercised according to the option program for 2017 at a strike
price of NOK 38.06;
· 73,500 options exercised according to the option program for 2019 at a
strike price of NOK 50.72; and
· 22,500 sign-on options exercised at a strike price of NOK 56.83.

Each option gives a right to receive one share in the Company. The share options
are described in note 7 and 20 in Photocure’s annual financial statements for
2019.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company’s Annual General Meeting, has decided to increase the
Company’s share capital by NOK 51,266.50 by issuing 102,533 new shares, of par
value NOK 0.50. Subsequent to the transaction, Photocure’s share capital will be
NOK 13,410,034.50 divided into 26,820,069 shares, each share having a par value
of NOK 0.50 and carrying one vote in the Company’s general meeting.

The following options are exercised by primary insiders:

· Dan Schneider, CEO, has exercised 50,000 options.
· Erik Dahl, CFO, has exercised 10,000 options.
· Geoffrey Coy, VP and General Manager of U.S. Operations, has exercised
22,500 options.
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
exercised 6,250 options.
· Kari Myren, VP Global Medical Affairs and Clinical Development, has
exercised 6,250 options.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

The primary insiders mentioned above have transferred their rights to receive
shares resulting from the exercise of options to a third party. Following a sale
of shares, the primary insiders will receive the net proceeds after deduction of
the strike price and accrued tax. The primary insiders will use the full net
proceeds to purchase shares in Photocure. The sales amount and the number of
shares purchased will be finally determined on the basis of the price
subsequently obtained by the third party in the market. The results of the sales
process will be announced in a separate stock exchange notice when known.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

TekBot · mars 26, 2021, 6:55am

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Oslo, Norway, 26 March 2020: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 25 March 2021
regarding initiation of a share buyback program.
…

Vis børsmeldingen

The Company has completed its share buyback program. The Company has acquired a
total of 33 041 own shares at a price per share of NOK 130.6672. A report of all
the transactions relating to the buy-back programme, in a detailed form and in
an aggregated form is attached.

The shares acquired is used for the Company’s incentive scheme and sold to
employees.

After the acquisition and sale to employees, Photocure owns 15,666 own shares in
the Company.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This is information is made public by the Company pursuant to the EU Market
Abuse Regulation article 5, as supplemented by Commission Delegated Regulation
(EU) 2016/1052, and is subject to the disclosure requirements pursuant to
Section 5-12 the Norwegian Securities Trading Act.

Kilde

TekBot · mars 26, 2021, 7:45am

Photocure ASA: Exercise of employee share options

Oslo, Norway, 26 March 2021: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 25 March 2021
regarding exercise of share options.
…

Vis børsmeldingen

The price for option shares sold by primary insiders have been determined at a
price of NOK 130.6672 per share.

The primary insiders having exercised options have used the net proceeds from
the sale of option shares to purchase shares in Photocure at a price per share
of NOK 130.6672 as follows:

· Dan Schneider, CEO, has purchased 17,980 shares.
· Erik Dahl, CFO, has purchased 3,236 shares.
· Geoffrey Coy, VP and General Manager of U.S. Operations, has purchased 8,081
shares.
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
purchased 1,872 shares.
· Kari Myren, VP Global Medical Affairs and Clinical Development, has
purchased 1,872 shares.

The shares are purchased at the stated price from Photocure’s holding of own
shares. Following the transaction Photocure will hold 15,666 own shares.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

TekBot · mars 29, 2021, 9:11am

Photocure ASA: Share capital increase registered

Oslo, Norway, 29 March 2021: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 25 March 2021
regarding a share capital increase following the exercise of share options.
…

Vis børsmeldingen

The issuance of 102,533 new shares has been registered with the Norwegian
Register of Business Enterprises. Following registration, the share capital of
Photocure is NOK 13,410,034.50 divided into 26,820,069 shares, each share having
a par value of NOK 0.50 and carrying one vote in the Company’s general meeting.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to sections
5-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · april 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (401 likes)

@Snoeffelen (126 likes)

[quote=“Snoeffelen, post:3801, topic:18877”]

@Savepig (117 likes)

Resten av topp 10:

@togulle (59 likes)
@tooeasy891 (56 likes)
@rosk82 (52 likes)
@solskimm (44 likes)
@Fornybar (41 likes)
@Boykie (28 likes)
@roblar (23 likes)

Gratulerer!

Savepig · april 2, 2021, 2:27pm

Pho topp 50 % er nå

60,4

januar: 55,54
juli i fjor: 52,83
april i fjor: 46,55

2021:

2020:

Ebitor · april 2, 2021, 3:03pm

Det mest markante i denne sammenheng er PHOs største aksjonær - Morgan Stanley LLC, som ukentlig akkumulerer.
Utskriften pr 22.03 viser nå en beholdning på 1.516.262 aksjer.
Om det skulle komme et bud på PHO, tror jeg nettopp at det kommer fra investoren bak dette finanskonsernet

Savepig · april 2, 2021, 4:32pm

En eller annen aktør med tilknytning til Boston Scientific er fremdeles min mistanke.

TekBot · april 6, 2021, 5:32am

Photocure to Present at Two Healthcare-Focused Investor Conferences in April

Press Release - Oslo, Norway, 6 April 2021, Photocure ASA (OSE: PHO), The
Bladder Cancer Company, announces that President and Chief Executive Officer,
Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present
…

Vis børsmeldingen

corporate overviews at two upcoming Healthcare Conferences in April.

Presentation details are as follows:
Solebury Trout European Biotech Investor Day: on April 7, 2021, Photocure
presents at 7:30pm CET / 1:30pm ET followed by individual investor meetings.
This virtual conference sponsored by Goodwin, Solebury Trout, Deutsche Bank and
NASDAQ showcases European biotech & healthcare companies.
You can sign up for the webcast
here (Loading...).

Needham Annual Healthcare Conference: on April 15, 2021, Photocure presents at
2:45pm CET / 8:45am ET followed by individual investor meetings. This 20[th]
annual conference is sponsored by the U.S. bank Needham & Company.
Access to the live event/webcast is available
here (https://wsw.com/webcast/needham107/pho.ol/2530528Photocure).

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Head of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media Enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

Kilde

TekBot · april 9, 2021, 6:09am

Photocure ASA – Major shareholding disclosure

rosk82 · april 9, 2021, 6:15am

Capture

Savepig · april 9, 2021, 6:16am

Må vel nesten være innenfor denne posten?

jovial · april 9, 2021, 7:21am

Så strategien er å investere i selskap som har noe risiko med høy potensiell oppside da deres investorer har begrensede midler.

stawk · april 9, 2021, 7:35am

Høres ikke umiddelbart ut som den mest langsiktige hovedaksjonær

Jeff · april 9, 2021, 7:58am

Kjøpt søk tilsier at det er et hedge fond med 530MUSD under forvaltning

Savepig · april 9, 2021, 1:24pm

Særdeles dype lommer blandt backerne til Briarwood:

Winklevoss Twins Eye Backing New Hedge Fund

Fund to Be Run By Fellow Harvard Graduate Aalap Mahadevia

2014 1:47 pm ET

Cameron and Tyler Winklevoss, the 32-year-old brothers famous for their legal tangle with Mark Zuckerberg and Facebook Inc., are examining a move to back a new hedge fund run by fellow Harvard College graduate Aalap Mahadevia, according to people with direct knowledge of the plans.

The fund, called Briarwood Chase Management LLC, would make the first hedge-fund investment by the pair’s family office, Winklevoss Capital. Briarwood Chase now operates out of the Winklevoss Capital offices in Manhattan’s Flatiron District.

Other Winklevoss Capital investments include Hukkster, Inc., a company that alerts consumers when items are on sale; Keepy Inc., an interactive scrapbook application; and AngelList, LLC, which helps startups raise money.

Ebitor · april 9, 2021, 2:15pm

Det er vel liten tvil om at konseptet til PHO fanger økende interesse over dammen.
At Cevira ser ut til å havne i Kina, øker sannsynligheten for at interessen for selskapet, som oppkjøpskandidat bare øker fra amerikansk hold.
Utvilsomt en god investering å sitte i PHO, slik også Snøffelen mener.
PHO seiler dessuten opp til å bli en attraktiv utbyttekandidat på litt sikt.

yrune · april 9, 2021, 2:51pm

Må være forsiktig med å nevne det her, kun vekst som gjelder tydeligvis for gjengen her
Personlig ser jeg det som høyst sansynlig at det kan skje allerede i år, jeg forventet det egentlig i fjor, men så skjedde det ganske mye annet covid, kjøp av europa rettigheter…

Det kan fort smelle inn noen store summer fra Kina også hvis de opprettholder tempo de har så langt. For ikke å glemme at de har nevnt at det jobbes med deals i andre verdensdeler.

TekBot · april 13, 2021, 6:29am